Lovenox
(Enoxaparin sodium)Phase 3Small molecule
SanofiEnoxaparin is a blood thinner used to prevent and treat blood clots, particularly in the legs and lungs, and to reduce the risk of clotting in patients undergoing surgery or those with heart conditions.[1] Lovenox is currently being investigated across 10 indications[3], with its most advanced program in Phase 3.[1]
Lovenox is one of 195 small molecule programs targeting Myocardial Infarction. It is currently in Phase 3.
10
Indications
34
Total Trials
4
Active Trials
194
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
89 competitors in Myocardial Infarction
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Neoral
NovartisApproved
Adenocard
AstellasApproved
Niacor
AbbVieApproved
Lovenox
SanofiPhase 3
Coreg
Akero TherapeuticsApproved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Alka-Seltzer
AAbbott
Approved
Truphylline
TThe Searle Company Limited Pakistan
Approved
Aurlumyn
BBTG International Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Venous Thromboembolism6 trials
Show 3 more trials
Total Knee Arthroplasty3 trials
Enoxaparin3 trials
COVID-192 trials
16 more indications
Venous thrombosis2 trials
Thromboembolism2 trials
Percutaneous Coronary Intervention (PCI)1 trial
PK/PD1 trial
Adult Subject1 trial
Chemotherapy1 trial
Acute Myocardial Infarction1 trial
Effectiveness1 trial
Prophylaxis1 trial
Fasting Conditions1 trial
Small Cell Lung Cancer1 trial
Acute Coronary Syndrome1 trial
Spinal Cord Injuries1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enoxaparin sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]